Adma Biologics, INC 8-K filings

ADMA Biologics reported Q1 2026 financial results with flat total revenue of $114.5 million, but saw a 22% increase in Adjusted Net Income to $40.7 million and a 24% rise in Adjusted EBITDA to $59.7 million, driven by strong ASCENIV performance and improved gross margins.

ADMA Biologics announces FDA approval to expand the label for its ASCENIV product to include pediatric immune compromised patients aged two years and older.

ADMA Biologics refutes allegations by Culper Research, asserting strong demand for its immune globulin products and standard inventory practices.

ADMA Biologics initiates a $125 million accelerated share repurchase as part of its $500 million program, signaling strong financial health and confidence in its stock.

ADMA Biologics announced record full-year 2025 financial results, driven by strong ASCENIV demand, and provided robust financial guidance through 2029, alongside a CFO transition.

ADMA Biologics announced preliminary unaudited full year 2025 revenue of $510-$511 million, exceeding prior guidance, and raised its financial outlook for 2026 and 2027.

ADMA Biologics reported robust third-quarter 2025 financial results, including a 12% revenue increase and 29% Adjusted EBITDA growth, while raising full-year 2025 and 2026 revenue guidance.

ADMA Biologics announced strong second quarter 2025 financial results, including significant revenue and earnings growth, alongside a $300 million debt refinancing and progress on key strategic initiatives like yield enhancement and infrastructure expansion.

ADMA Biologics, Inc. announced the successful passage of all proposals at its 2025 Annual Meeting of Stockholders, including the election of two Class III directors, ratification of KPMG LLP as auditor, and approval of executive compensation on an annual basis.

ADMA Biologics announces impressive Q1 2025 financial results with significant year-over-year growth and authorizes a substantial share repurchase program.

ADMA Biologics announces FDA approval for its innovative production yield enhancement process, expected to increase production yields by approximately 20%.

ADMA Biologics announced a 65% year-over-year increase in total revenue for 2024, reaching $426.5 million, and provided optimistic financial guidance for 2025 and 2026.

ADMA Biologics' Board of Directors approves salary increases, bonuses, and equity grants for key executives and adjusts director compensation.

ADMA Biologics showcases its vertically integrated business model, strong financial growth, and pipeline expansion opportunities in a recent corporate presentation.

ADMA Biologics reports preliminary 2024 revenue exceeding expectations, alongside significant cash growth and positive future financial guidance.

ADMA Biologics has appointed Eduardo Rene Salas, a seasoned financial executive, to its Board of Directors as a Class I director.

ADMA Biologics has announced a $30 million repayment of its senior secured term loan, funded by cash on hand, reducing total debt by 29%.

ADMA Biologics reports the resignation of a board member and the appointment of new members to key committees.

ADMA Biologics announced a strong third quarter in 2024, with significant year-over-year revenue and profit growth, leading to increased financial guidance for 2024 and 2025.

ADMA Biologics has engaged KPMG as its new independent registered public accounting firm, effective after the filing of the Q3 2024 report.

ADMA Biologics confirms that the recent change in auditors will not affect its previously issued financial guidance for 2024-2025.

ADMA Biologics' current independent auditor, CohnReznick LLP, has resigned, effective after the filing of the Q3 2024 report, prompting the company to begin the search for a new auditor.

ADMA Biologics has announced a $30 million repayment of its revolving credit facility, funded by cash on hand, leading to a 22% reduction in total debt.

ADMA Biologics announced a significant increase in revenue and profitability for the second quarter of 2024, leading to an upward revision of its full-year financial guidance.

ADMA Biologics has promoted Brad Tade to Chief Financial Officer and Treasurer, effective July 24, 2024.

ADMA Biologics has amended its bylaws, reducing the threshold for removing a director with cause and establishing Delaware courts as the exclusive forum for certain legal proceedings.

ADMA Biologics successfully held its 2024 Annual Meeting, electing three Class II directors and ratifying the appointment of its independent auditor.

ADMA Biologics is a vertically integrated biopharmaceutical company focused on manufacturing and marketing specialty biologics, particularly immunoglobulins, with a strong growth outlook.

ADMA Biologics announced a strong first quarter of 2024, with significant revenue and earnings growth, leading to increased financial guidance for the full year and beyond.

ADMA Biologics has promoted Kaitlin Kestenberg to Chief Operating Officer and Senior Vice President, Compliance, effective April 1, 2024.